Summary
The effects of pharmacological intervention on brain muscarinic cholinergic receptor (mAChR) binding were assessed in seven patients with Parkinson's disease by positron emission tomography and carbon-11 labelled N-methyl-4-piperidyl benzilate ([11C]NMPB). [11C]NMPB was injected twice, approximately 2 hours apart, in each patient, to assess the effect of single doses of 4 mg of trihexyphenidyl (n=5) or 400 mg of L-dopa with 57 mg of benserazide (n=2) on the binding parameter of mAChRs (K3). There was a mean 28% inhibition of K3 values in the brain in the presence of trihexyphenidyl, which was assumed to reflect mAChR occupancy. No significant change in K3 was observed in the presence of L-dopa. This study demonstrates the feasibility of measuring mAChR occupancy by an anticholinergic medication with PET.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anderson U, Eckernäs S-A, Hartvig P, Ulin J, Långström B, Häggström J-E (1990) Striatal binding of11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J Neural Transm [GenSect] 79: 215–226
Biel JH, Abood LG, Hoya WK, Leiser HA, Nuhfer PA, Kluchesky EF (1961) Central stimulants. II. Cholinergic blocking agents. J Org Chem 26: 4096–4103
Bonner TI (1989) The molecular basis of muscarinic receptor density. TINS 12: 148–151
Burke RE, Fahn S (1982) Pharmacolinetics of trihexyphenidyl after acute and chronic administration. Ann Neurol 12: 94
Davies P, Verth AH (1978) Regional distribution of muscarinic acetylcholine receptor in normal and Alzheimer's-type dementia brains. Brain Res 138: 385–392
Dewey SL, MacGregor RR, Brodie JD, Bendriem B, King PT, Volkow ND, Schlyer DJ, Fowler JS, Wolf AP, Gatley SJ, Hitzemann R (1990) Mapping muscarinic receptors in human and baboon brain using [N-11C-Methyl]-Benztropine. Synapse 5: 213–223
Dewey SL, Brodie JD, Fowler S, MacGregor RR, Schlyer DJ, King PT, Alexoff DL, Volkow ND, Shiue CY, Wolf AP, Bendriem B (1990) Positron emission tomography (PET) studies of dopaminergic/cholinergic interactions in the baboon brain. Synapse 6: 321–327
Eckernäs SÅ, Aquilonius SM, Hartvig P, Hägglund J, Lundqvist H, Någren K, Långström B (1987) Positron emission tomography (PET) in the study of dopamine receptors in the primate brain: evaluation of a kinetic model using11C-N-methylspiperone. Acta Neurol Scand 75: 168–178
Endo M, Fukuda H, Suhara T, Matsumoto T, Iinuma T, Yamasaki T, Tateno Y, Nohara N, Ogushi A, Kumamoto M, Inoue S (1991) Design and performance of PCT-3600W (15-slice type): a whole-body positron emission tomograph. J Nucl Med 32: 1061
Frey KA, Koeppe RA, Mulholland GK, Jewett D, Hichwa R, Ehrenkaufer RLE, Carey JE, Wieland DM, Kuhl DE, Agranoff BW (1992) In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography. J Cereb Blood Flow Metab 12: 147–154
Gjedde A, Wong DF (1990) Modeling neuroreceptor binding of radioligands in vivo. In: Frost JJ, Wagner HN (eds) Quantitative imaging: neuroreceptors, neurotransmitters, and enzymes. Raven Press, New York, pp 51–79
Honer WG, Prohovnik I, Smith G, Lucas LR (1988) Scopolamine reduces frontal cortex perfusion. J Cereb Blood Flow Metab 8: 635–641
Huang SC, Barrio JR, Phelps ME (1986) Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 6: 515–521
Koeppe RA, Frey KA, Zubieta JA, Fessler JA, Mulholland GK, Kilbourn MR, Mangner TJ, Kuhl DE (1992) Tracer kinetic analysis of [C-11]N-methyl-4-piperidyl benzilate binding to muscarinic cholinergic receptors. J Nucl Med 33: 882
Koller WC (1987) Handbook of Parkinson's disease, 1st edn. Marcel Dekker, New York Basel, pp 482–488
Lin SC, Olson KC, Okazaki H, Richelson E (1986) Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine. J Neurochem 46: 274–279
MacKenzie RG, Stachowiak MK, Zigmond MJ (1989) Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine. Eur J Pharmacol 168: 43–52
Matsui T, Hirano A (1976) An atlas of the human brain for computerized tomography. Igaku Shoin Ltd, Tokyo
Mei L, Roeske WR, Yamamura HI (1989) Molecular pharmacology of muscarinic receptor heterogeneity. Life Sci 45: 1831–1851
Mulholland GK, Otto CA, Jewett DM, Kilbourn MR, Koeppe RA, Sherman PS, Petry NA, Carey JE, Atkinson ER, Archer S, Frey KA, Kuhl DE (1992) Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2-tropanyl benzilate: a central muscarinic receptor imaging agent. J Nucl Med 33: 423–430
Nordström AL, Farde L, Halldin C (1992) Time course of D2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 106: 433–438
Obeso JA, Martinez-Lange JM (1987) Anticholinergics and amantadine. In: Koller WC (ed) Handbook of Parkinson's disease. Marcel Dekker, New York Basel, pp 309–316
Otto CA, Mulholland GK, Perry SE, Combs R, Sherman PS, Fisher SJ (1989) In vitro and ex vivo evaluation of cyclic aminoalkyl benzilates as potential emission tomography ligands for the muscarinic receptor. Nucl Med Biol 16: 51–55
Rehavi M, Yaavetz B, Kloog Y, Maayani S, Sokolovsky M (1978) In vivo and in vitro studies on the antimuscarinic activity of some amino esters of benzilic acid. Biochem Pharmacol 27: 1117–1124
Shinotoh H, Iyo M, Yamada T, Inoue O, Suzuki K, Itoh T, Fukuda H, Yamasaki T, Tateno Y, Hirayama K (1989) Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography. Psychopharmacology 99: 202–207
Stoof JC, Drukarch B, De Boer P, Westerink BHC, Groenewegen HJ (1992) Regulation of the activity of striatal cholinergic neurons by dopamine. Neuroscience 47: 755–770
Suhara T, Inoue O, Kobayashi K, Suzuki K, Tateno Y (1993) Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. Neurosci Lett 149: 225–228
Suzuki K, Inoue O, Hashimoto K, Yamasaki T, Kuchiki M, Tamate K (1985) Computer controlled large scale production of high specific activity [11C]Ro15-1788 for PET studies of benzodiazepine receptors. Int J Appl Radiat Isot 36: 971–976
Tejani-Butt SM, Luthin GR, Wolfe BB, Brunswick DJ (1990) N-substituted derivatives of 4-piperidinyl benzilate: affinities for brain muscarinic acetylcholine receptors. Life Sci 47: 841–848
Trabucchi M, Cheney DL, Racagni G, Costa E (1975) In vivo inhibition of striatal acetylcholine turnover by L-DOPA, apomorphine and (+)-amphetamine. Brain Res 85: 130–134
Varastet M, Brouillet E, Chavoix C, Prenant C, Crouzel C, Stulzaft O, Bottlaender M, Cayla J, Mazière B, Mazière M (1992) In vivo visualization of central muscarinic receptors using [11C]quinuclidinyl benzilate and positron emission tomography in baboons. Eur J Pharmacol 213: 275–284
Wong DF, Wagner HN, Dannals RF, Links JM, Fronst JJ, Ravert HT, Wilson AA, Rosenbaum AE, Gjedde A, Douglass KH, Petronis JD, Folstein MF, Toung JKT, Burns HD, Kuhar MJ (1984) Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science 226: 1393–1396
Wong DF, Gjedde A, Wagner HN (1986) Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands. J Cereb Blood Flow Metab 6: 137–146
Zubieta JK, Frey KA, Koeppe RA, Kuhl DE (1993) Quantification of muscarinic receptors in vivo with [C-11]NMPB and PET: distinction of ligand delivery and binding. J Nucl Med 34: 108P
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shinotoh, H., Asahina, M., Inoue, O. et al. Effects of trihexyphenidyl and L-dopa on brain muscarinic cholinergic receptor binding measured by positron emission tomography. J Neural Transm Gen Sect 7, 35–46 (1994). https://doi.org/10.1007/BF02252661
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02252661